Weight Loss

Search documents
Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
GlobeNewswire News Room· 2025-06-17 13:00
Core Insights - Omada Health's GLP-1 companion program significantly enhances medication persistence rates for GLP-1 medications, leading to improved weight loss outcomes comparable to clinical trials [1][2][4] Group 1: Medication Persistence and Weight Loss - Omada's analysis of 1,124 members showed that those who adhered to their GLP-1 medication for 24 weeks had a persistence rate of 84%, compared to lower rates in previous studies [2][4] - Members who maintained their medication lost an average of 12.1% of their body weight over 24 weeks, while those who discontinued early lost only 7.4%, indicating a 64% relative increase in weight loss for persistent users [2][4] Group 2: Support and Resources - The Enhanced GLP-1 Care Track provides targeted resources, including education on dose titration, side effects, nutrition guidance, and exercise support, to help members overcome barriers to medication persistence [3][4] - Omada aims to ensure that increased access to GLP-1 medications translates into sustainable long-term health benefits through enhanced support and engagement in healthy lifestyle changes [4][5] Group 3: Company Overview and Impact - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and 29 peer-reviewed publications demonstrating its clinical and economic effectiveness [5][6] - The company serves more than 2,000 customers, including health plans and employers, and emphasizes a strong work culture, earning recognition as a Great Place to Work® [5][6]
Allurion Technologies(ALUR) - 2024 Q4 - Earnings Call Presentation
2025-03-26 12:57
Investor Presentation March 2025 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this "presentation") contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the "Company" or "us") and is provided to the recipients ("you") of this presentation on the condition that you agree to hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part to others at any time withou ...